Document Detail


Oncogenic K-Ras requires activation for enhanced activity.
MedLine Citation:
PMID:  23334325     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Oncogenic Ras mutations are widely considered to be locked in a permanent 'On' state and 'constitutively active'. Yet, many healthy people have cells possessing mutant Ras without apparent harm, and in animal models mutant Ras causes transformation only after upregulation of Ras activity. Here, we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity. These data indicate that in addition to targeting K-Ras downstream effectors, interventions to reduce K-Ras activation may have important cancer-preventive value, especially in patients with oncogenic Ras mutations. As other small G proteins are regulated in a similar manner, this concept is likely to apply broadly to the entire Ras family of molecules.
Authors:
H Huang; J Daniluk; Y Liu; J Chu; Z Li; B Ji; C D Logsdon
Related Documents :
19373855 - Activation of the erk/mapk pathway: a signature genetic defect in posterior fossa piloc...
19243475 - Serum regulates adipogenesis of mesenchymal stem cells via mek/erk-dependent ppargamma ...
24691965 - The egfr family: not so prototypical receptor tyrosine kinases.
12946695 - Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinas...
3160705 - Activation of protein kinase c by triton x-100 mixed micelles containing diacylglycerol...
2153115 - Selective killing of klebsiella pneumoniae by 5-trifluoromethylthioribose. chemotherape...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2013-01-21
Journal Detail:
Title:  Oncogene     Volume:  33     ISSN:  1476-5594     ISO Abbreviation:  Oncogene     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2014-01-23     Completed Date:  2014-03-11     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  8711562     Medline TA:  Oncogene     Country:  England    
Other Details:
Languages:  eng     Pagination:  532-5     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blotting, Western
Cell Line, Tumor
Cell Transformation, Neoplastic / genetics,  metabolism*
Electrophoresis, Polyacrylamide Gel
Genes, ras / genetics
Humans
Mice
Mice, Mutant Strains
Mutation
Neoplasms / genetics,  metabolism*
Proto-Oncogene Proteins p21(ras) / genetics*,  metabolism
Grant Support
ID/Acronym/Agency:
CA016672/CA/NCI NIH HHS; CA155165/CA/NCI NIH HHS; DK052067/DK/NIDDK NIH HHS; K12 CA090628/CA/NCI NIH HHS; P20 CA101936/CA/NCI NIH HHS; P20 CA101936/CA/NCI NIH HHS; P30 CA016672/CA/NCI NIH HHS; P50 CA102701/CA/NCI NIH HHS; P50 CA102701/CA/NCI NIH HHS; R01 DK052067/DK/NIDDK NIH HHS; R21 CA155165/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
EC 3.6.5.2/Kras2 protein, mouse; EC 3.6.5.2/Proto-Oncogene Proteins p21(ras)
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer.
Next Document:  The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transi...